Weight gain: A side effect of zotepine (Nipolept®)?;Gewichtszunahme: Eine nebenwirkung von zotepin (Nipolept®)? Eine anwendungsbeobachtung

Nervenarzt

Volumn 67, Issue 3, 1996, Pages 256-261

  Wetterling, T ^a   Mussigbrodt H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Neuroleptics; Side effects; Weight; Zotepine

Indexed keywords

BENPERIDOL; BROMPERIDOL; CHLORPROTHIXENE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERAZINE; PIMOZIDE; ZOTEPINE;

ADULT; ARTICLE; DELUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DELUSIONS; DIBENZOTHIEPINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0030009438     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ackenheil M (1991) Das biochemische Wirkprofil von Zotepin im Vergleich zu anderen Neuroleptika. Fortschr Neurol Psychiat 59 [Suppl 1]: 2-9
2. Amidsen A (1964) Drug produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 11:182-189
3. Chouinard G, Annable L, Kropsky M (1978) Pipothiazine in schizophrenia. J Clin Pharmacol 18: 148-154
4. Cohen S, Chiles J, MacNaughton A (1990) Weight gain associated with clozapine. Am J Psychiatry 147: 503-504
5. 2 receptors. Pharmacopsychiatry 26: 53-58
6. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP (1991) Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 54: 321-325
7. Dilling H, Mombour W, Schmidt MH (1993) Internationale Klassifikation psychischer Störungen ICD-10, 2. Aufl. Huber, Bern
8. Falloon I, Watt D, Shephard M (1978) Pimozide and fluphenazine decanoate in continuation therapy. Psychol Med 8: 59-70
9. Garattini S, Caccia S, Mennini T, Samanin R, Consol S, Ladinski H (1987) Biochemical pharmacology of the anorectic drug fenfluramine: a review. Curr Med Res Opin 1: 15-27
10. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T (1988) A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 153: 208-213
11. Goncalves N, Grüneberg F (1975) Einzeitige orale Glukosebelastung bei langfristig behandelten Schizophrenen. Pharmakopsychiatrie 8: 289-295
12. Harris E, Eth S (1981) Weight gain during neuroleptic treatment. Int J Nurs Studies 18: 171-175
13. Hökfelt T, Johansson O, Holds V, Meister B, Melander T (1987) Distribution of neuropeptides with special reference to their coexistence with classical neurotransmitters. In: Meltzer HY (ed) Psychopharmacology. 3rd generation of progress. Raven, New York, pp407-416
14. Johnson DA, Breen M (1979) Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 59: 525-528
15. Korsgaard S, Skausig OB (1979) Increase in weight after treatment with depot neuroleptics. Acta Psychiatr Scand 59: 139-144
16. Lamperti JS, Bellnier T, Schwarzkopf SB (1992) Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 149: 689-690
17. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149: 68-72
18. Lehnert H, Schrezenmeir J, Beyer J (1990) Zentralnervöse Appetitregulation: Mechanismen und Bedeutung für die Entstehung der Adipositas. Z Ernährungswiss 29: 2-12
19. Marriott P, Pansa M, Hiep A (1981) Depot fluphenazine maintenance treatment and associated weight changes. Comp Psychiatry 22: 320-325
20. McCreadie RG, Todd N, Livingston M, Eccleson D, Watt JAG, Herrington RN, Tait D, Crocket G, Mitchell MJ, Huitfeld B (1990) A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand 82 [Suppl 358]: 136-137
21. Mertens C (1992) Risperidone treatment in psychotic patients: a combined analysis of the data of three open long-term trials. Jansen Clinical Research Report
22. Müller-Oerlinghausen B (1986) Wirkung von Lithiumsalzen auf Kohlenhydratstoffwechsel. Körpergewicht und gastrointestinale Funktionen. In: Müller-Oerlinghausen B, Greil W (Hrsg) Die Lithiumtherapie. Springer, Berlin Heidelberg New York, S 297-304
23. Nutzinger DO, de Zwaan M, Schonbeck G (1991) Serotonin und Eßstörungen. Nervenarzt 62: 198-201
24. Robinson RG, McHugh PR, Folstein MF (1975) Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 12: 59-68
25. Schony W, Rittmannsberger H (1992) Praktische Durchführung, allgemeine Behandlungsrichtlinien. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd4. Neuroleptika. Springer, Wien, S131-155
26. Silverstone T, Smith G, Goodall E (1988) Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 153: 214-217
27. Wetterling T (1987) Hyponatriämie - unterschätzte Komplikation bei psychiatrischen Patienten. Nervenarzt 58: 625-631
28. Wise SD (1992) Clinical studies with fluoxetine in obesity. Am J Clin Nutr 55: S181-S184
29. Wurtman JJ, Wurtman RJ (1979) Drugs that enhance central serotonergic transmission diminish elective carbohydrate consumption by rats. Life Sci 24: 895-904